NO991423D0 - Qinolinderivater som inhiberer effekten av vekstfaktorer som VEGF - Google Patents
Qinolinderivater som inhiberer effekten av vekstfaktorer som VEGFInfo
- Publication number
- NO991423D0 NO991423D0 NO991423A NO991423A NO991423D0 NO 991423 D0 NO991423 D0 NO 991423D0 NO 991423 A NO991423 A NO 991423A NO 991423 A NO991423 A NO 991423A NO 991423 D0 NO991423 D0 NO 991423D0
- Authority
- NO
- Norway
- Prior art keywords
- formula
- 3alkyl
- nitro
- alkyl
- optionally substituted
- Prior art date
Links
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 239000003102 growth factor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- -1 C1-3alkanoyloxy Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000005647 linker group Chemical group 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 241000282412 Homo Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001603 reducing effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000008728 vascular permeability Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96402034 | 1996-09-25 | ||
| PCT/GB1997/002587 WO1998013350A1 (en) | 1996-09-25 | 1997-09-23 | Qinoline derivatives inhibiting the effect of growth factors such as vegf |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO991423D0 true NO991423D0 (no) | 1999-03-24 |
| NO991423L NO991423L (no) | 1999-05-11 |
| NO321003B1 NO321003B1 (no) | 2006-02-27 |
Family
ID=8225290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19991423A NO321003B1 (no) | 1996-09-25 | 1999-03-24 | Kinolinderivater som inhiberer effekten av vekstfaktorer som VEGF, anvendelse og fremstilling derav, samt farmasoytisk sammensetning. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6809097B1 (no) |
| EP (1) | EP0929526B1 (no) |
| JP (1) | JP2001500890A (no) |
| KR (1) | KR100567649B1 (no) |
| CN (1) | CN1252054C (no) |
| AT (1) | ATE300521T1 (no) |
| AU (1) | AU733551B2 (no) |
| CA (1) | CA2263479A1 (no) |
| DE (1) | DE69733825T2 (no) |
| IL (1) | IL128994A (no) |
| NO (1) | NO321003B1 (no) |
| NZ (1) | NZ334125A (no) |
| WO (1) | WO1998013350A1 (no) |
Families Citing this family (140)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143764A (en) * | 1995-11-07 | 2000-11-07 | Kirin Beer Kabushiki Kaisha | Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same |
| GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| WO1999010349A1 (en) | 1997-08-22 | 1999-03-04 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
| JP2002522475A (ja) * | 1998-08-13 | 2002-07-23 | ノバルティス アクチエンゲゼルシャフト | 眼血管新生疾患の処置方法 |
| US6630488B1 (en) | 1998-09-21 | 2003-10-07 | Biochem Pharma, Inc. | Quinolizinones as integrin inhibitors |
| US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| US6288082B1 (en) | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| EP1950201A1 (en) | 1998-09-29 | 2008-07-30 | Wyeth Holdings Corporation | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors |
| US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| EE05345B1 (et) * | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| GB9904103D0 (en) | 1999-02-24 | 1999-04-14 | Zeneca Ltd | Quinoline derivatives |
| US6548496B2 (en) | 1999-04-21 | 2003-04-15 | American Cyanamid Company | Substituted 3-cyano-[1.7], [1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases |
| US6355636B1 (en) | 1999-04-21 | 2002-03-12 | American Cyanamid Company | Substituted 3-cyano-[1.7],[1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases |
| DE60009888T2 (de) * | 1999-04-21 | 2005-04-21 | Wyeth Corp | Substituierte 3-cyano-[1.7], [1.5] und [1.8]naphthyridininhibitoren von tyrosin kinasen |
| GB9910579D0 (en) | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| GB9910577D0 (en) * | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| GB9910580D0 (en) * | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| US6432979B1 (en) | 1999-08-12 | 2002-08-13 | American Cyanamid Company | Method of treating or inhibiting colonic polyps and colorectal cancer |
| WO2001028993A2 (en) * | 1999-10-19 | 2001-04-26 | Merck & Co. Inc. | Tyrosine kinase inhibitors |
| KR100881105B1 (ko) | 1999-11-05 | 2009-02-02 | 아스트라제네카 아베 | Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체 |
| US6638929B2 (en) | 1999-12-29 | 2003-10-28 | Wyeth | Tricyclic protein kinase inhibitors |
| AU2001231710A1 (en) | 2000-02-09 | 2001-08-20 | Novartis Ag | Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase |
| DE60112268T2 (de) | 2000-03-06 | 2006-05-24 | Astrazeneca Ab | Verwendung von quinazolinderivate als inhibitoren der angiogenese |
| US6521618B2 (en) | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| AR035851A1 (es) * | 2000-03-28 | 2004-07-21 | Wyeth Corp | 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas |
| US6608048B2 (en) | 2000-03-28 | 2003-08-19 | Wyeth Holdings | Tricyclic protein kinase inhibitors |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| DE60121931T2 (de) * | 2000-04-07 | 2007-03-01 | Astrazeneca Ab | Chinazolinverbindungen |
| MXPA02012943A (es) * | 2000-08-09 | 2003-05-15 | Astrazeneca Ab | Compuestos de cinolina. |
| MXPA03000252A (es) * | 2000-08-09 | 2003-06-06 | Astrazeneca Ab | Derivados de quinolina que tienen actividad de inhibicion de fcev. |
| BR0113078A (pt) * | 2000-08-09 | 2003-07-01 | Astrazeneca Ab | Uso de um composto, composto, processo para a preparação do mesmo, composição farmacêutica, e, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente |
| AU2001277621A1 (en) * | 2000-08-09 | 2002-03-04 | Astrazeneca Ab | Antiangiogenic bicyclic derivatives |
| ATE448226T1 (de) | 2000-09-01 | 2009-11-15 | Novartis Vaccines & Diagnostic | Aza heterocyclische derivate und ihre therapeutische verwendung |
| KR100732206B1 (ko) | 2000-09-11 | 2007-06-27 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 티로신 키나제 억제제로서의 퀴놀리논 유도체 |
| JP2004517860A (ja) | 2000-10-12 | 2004-06-17 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類 |
| NZ525088A (en) | 2000-10-12 | 2004-11-26 | Merck & Co Inc | Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors |
| DE60128936T2 (de) | 2000-10-12 | 2008-04-10 | Merck & Co, Inc. | Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer |
| HU230302B1 (hu) | 2000-10-20 | 2015-12-28 | Eisai R&D Management Co., Ltd. | Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények |
| EP1337524A1 (en) | 2000-11-02 | 2003-08-27 | AstraZeneca AB | Substituted quinolines as antitumor agents |
| AU2001295791A1 (en) | 2000-11-02 | 2002-05-15 | Astrazeneca Ab | 4-substituted quinolines as antitumor agents |
| US6603005B2 (en) | 2000-11-15 | 2003-08-05 | Aventis Pharma S.A. | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them |
| KR100883184B1 (ko) | 2000-12-11 | 2009-02-12 | 암젠 인코포레이션 | Ｃｘｃｒ3 길항제 |
| GB0104422D0 (en) * | 2001-02-22 | 2001-04-11 | Glaxo Group Ltd | Quinoline derivative |
| US6602884B2 (en) | 2001-03-13 | 2003-08-05 | Aventis Pharma S.A. | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them |
| US6794379B2 (en) | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
| PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
| ATE341545T1 (de) | 2001-07-16 | 2006-10-15 | Astrazeneca Ab | Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase |
| AR036256A1 (es) | 2001-08-17 | 2004-08-25 | Merck & Co Inc | Sal sodica de un inhibidor de integrasa del vih, procesos para su preparacion, composiciones farmaceuticas que lo contienen y su uso para la manufactura de un medicamento |
| US20060004437A1 (en) | 2001-08-29 | 2006-01-05 | Swaminathan Jayaraman | Structurally variable stents |
| MXPA04007459A (es) * | 2002-02-01 | 2005-09-08 | Astrazeneca Ab | Compuestos de quinazolina. |
| AU2003220170B2 (en) | 2002-03-15 | 2008-12-11 | Merck Sharp & Dohme Corp. | N-(Substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as HIV integrase inhibitors |
| EP1513840B1 (en) * | 2002-05-31 | 2006-10-04 | Bayer Pharmaceuticals Corporation | Compounds and compositions for the treatment of diabetes and diabetes-related disorders |
| WO2004006846A2 (en) | 2002-07-15 | 2004-01-22 | Exelixis, Inc. | Receptor-type kinase modulators and methods of use |
| US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
| CN100526312C (zh) * | 2002-08-23 | 2009-08-12 | 诺华疫苗和诊断公司 | 苯并咪唑喹啉酮及其应用 |
| KR100942073B1 (ko) | 2002-08-23 | 2010-02-12 | 기린 홀딩스 가부시키가이샤 | ＴＧＦ β 저해 활성을 갖는 화합물 및 그것을 포함하여 이루어지는 의약 조성물 |
| US7470709B2 (en) | 2002-08-23 | 2008-12-30 | Novartis Vaccines And Diagnostics, Inc. | Benzimidazole quinolinones and uses thereof |
| GB0225579D0 (en) * | 2002-11-02 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
| WO2004041829A1 (en) * | 2002-11-04 | 2004-05-21 | Astrazeneca Ab | Quinazoline derivatives as src tyrosine kinase inhibitors |
| WO2004043367A2 (en) | 2002-11-06 | 2004-05-27 | Bristol-Myers Squibb Company | Fused heterocyclic compounds and use thereof |
| JP2006511616A (ja) | 2002-11-13 | 2006-04-06 | カイロン コーポレイション | 癌の処置方法およびその関連方法 |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| CA2744997A1 (en) | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and method of use |
| EP2762475A1 (en) | 2003-11-07 | 2014-08-06 | Novartis Vaccines and Diagnostics, Inc. | Pharmaceutically acceptable salts of quinolinone compounds and their medical use |
| CN100450998C (zh) | 2003-11-11 | 2009-01-14 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
| GEP20084572B (en) | 2003-12-23 | 2008-12-25 | Pfizer | Novel quinoline derivatives |
| WO2005080377A1 (ja) * | 2004-02-20 | 2005-09-01 | Kirin Beer Kabushiki Kaisha | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
| CN1960731B (zh) | 2004-02-20 | 2011-12-07 | 诺华疫苗和诊断公司 | 调节炎性和转移过程的方法 |
| WO2005115145A2 (en) * | 2004-05-20 | 2005-12-08 | Wyeth | Quinone substituted quinazoline and quinoline kinase inhibitors |
| EP1797881B1 (en) | 2004-09-17 | 2009-04-15 | Eisai R&D Management Co., Ltd. | Medicinal composition with improved stability and reduced gelation properties |
| AU2006231646A1 (en) * | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-Met modulators and methods of use |
| BRPI0610355A2 (pt) | 2005-05-17 | 2010-06-15 | Novartis Ag | métodos par sintetizar compostos heterocìclicos |
| EP2270000B1 (en) | 2005-05-23 | 2015-07-29 | Novartis AG | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts |
| EP2281901B1 (en) | 2005-08-02 | 2013-11-27 | Eisai R&D Management Co., Ltd. | Anti-tumour pharmaceutical composition with angiogenesis inhibitors |
| TW200730176A (en) | 2005-11-29 | 2007-08-16 | Novartis Ag | Formulations of quinolinones |
| WO2007081517A2 (en) | 2005-12-21 | 2007-07-19 | Abbott Laboratories | Anti-viral compounds |
| RU2441010C2 (ru) * | 2005-12-21 | 2012-01-27 | Эбботт Лэборетриз | Противовирусные соединения |
| DE602006015861D1 (de) | 2005-12-21 | 2010-09-09 | Abbott Lab | Antivirale verbindungen |
| EP2345652A1 (en) | 2005-12-21 | 2011-07-20 | Abbott Laboratories | Antiviral compounds |
| TW200738707A (en) * | 2005-12-21 | 2007-10-16 | Abbott Lab | Anti-viral compounds |
| ES2378473T3 (es) * | 2005-12-21 | 2012-04-12 | Abbott Laboratories | Compuestos antivirales |
| RU2442777C2 (ru) | 2006-01-31 | 2012-02-20 | Эррэй Биофарма Инк. | Ингибиторы киназ и способы их применения |
| WO2007113548A1 (en) * | 2006-04-06 | 2007-10-11 | Astrazeneca Ab | Naphthyridine derivatives |
| US7601716B2 (en) * | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
| EP2036557B1 (en) | 2006-05-18 | 2015-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| CN101511793B (zh) | 2006-08-28 | 2011-08-03 | 卫材R&D管理有限公司 | 针对未分化型胃癌的抗肿瘤剂 |
| EP2094276A4 (en) | 2006-12-20 | 2011-01-05 | Abbott Lab | ANTIVIRAL COMPOUNDS |
| AU2008211952B2 (en) | 2007-01-29 | 2012-07-19 | Eisai R & D Management Co., Ltd. | Composition for treatment of undifferentiated-type of gastric cancer |
| US20080190689A1 (en) * | 2007-02-12 | 2008-08-14 | Ballard Ebbin C | Inserts for engine exhaust systems |
| US20080234267A1 (en) * | 2007-03-20 | 2008-09-25 | Karen Elizabeth Lackey | Compounds and Methods of Treatment |
| CA2685888A1 (en) * | 2007-05-09 | 2008-11-20 | Pfizer Inc. | Substituted heterocyclic derivatives and their pharmaceutical use and compositions |
| JP5638244B2 (ja) | 2007-11-09 | 2014-12-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質と抗腫瘍性白金錯体との併用 |
| CN101945869B (zh) | 2007-12-19 | 2014-06-18 | 癌症研究技术有限公司 | 吡啶并[2,3-b]吡嗪-8-取代化合物及其用途 |
| GB0807609D0 (en) | 2008-04-25 | 2008-06-04 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CN101570530B (zh) * | 2008-04-30 | 2011-08-17 | 上海医药工业研究院 | 一种黄酮类二聚物的制备方法、及中间体及其制备方法 |
| WO2010005527A1 (en) | 2008-06-30 | 2010-01-14 | Angioblast Systems, Inc. | Treatment of eye diseases and excessive neovascularization using a combined therapy |
| EP2291376A2 (en) * | 2008-07-03 | 2011-03-09 | Merck Patent GmbH | Naphthyridininones as aurora kinase inhibitors |
| JP5486606B2 (ja) * | 2008-11-13 | 2014-05-07 | エクセリクシス， インク． | キノリン誘導体の調製方法 |
| JP2012511017A (ja) * | 2008-12-04 | 2012-05-17 | エグゼリクシス， インコーポレイテッド | キノリン誘導体の調製方法 |
| KR101733773B1 (ko) | 2009-01-16 | 2017-05-10 | 엑셀리시스, 인코포레이티드 | Ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| CN102030705B (zh) * | 2009-09-30 | 2012-12-19 | 上海睿智化学研究有限公司 | 7-苄氧基-6-甲氧基-4-羟基喹啉的合成方法 |
| KR101086456B1 (ko) * | 2009-10-15 | 2011-11-25 | 한국원자력의학원 | 이미다조퓨린 유도체를 포함하는 ＴＧＦ-β 활성 저해용 조성물 |
| WO2011092469A1 (en) | 2010-02-01 | 2011-08-04 | Cancer Research Technology Limited | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| JP2013526484A (ja) * | 2010-05-07 | 2013-06-24 | グラクソ グループ リミテッド | キナーゼ阻害剤としてのアミノ‐キノリン |
| MX2012014776A (es) | 2010-06-25 | 2013-01-29 | Eisai R&D Man Co Ltd | Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados. |
| UY33549A (es) * | 2010-08-10 | 2012-01-31 | Glaxo Group Ltd | Quinolil aminas como agentes inhibidores de las quinasas |
| EA023998B1 (ru) * | 2011-03-04 | 2016-08-31 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Аминохинолины в качестве ингибиторов киназ |
| MX2013009931A (es) | 2011-04-18 | 2013-10-01 | Eisai R&D Man Co Ltd | Agentes terapeuticos contra tumores. |
| US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| DK2780338T3 (en) | 2011-11-14 | 2016-12-19 | Ignyta Inc | Uracil AS AXL- AND C-MET kinase inhibitors |
| AR092530A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| TWI592417B (zh) | 2012-09-13 | 2017-07-21 | 葛蘭素史克智慧財產發展有限公司 | 胺基喹唑啉激酶抑制劑之前藥 |
| CN103709162B (zh) * | 2012-09-29 | 2016-12-07 | 中国科学院上海药物研究所 | 三取代咪唑并二氮杂萘酮化合物及其制备方法和用途 |
| US9334239B2 (en) | 2012-12-21 | 2016-05-10 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| JP6301374B2 (ja) | 2013-02-21 | 2018-03-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | キナーゼ阻害剤としてのキナゾリン類 |
| US10517861B2 (en) | 2013-05-14 | 2019-12-31 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| CN106660964B (zh) | 2014-08-28 | 2021-09-03 | 卫材R&D管理有限公司 | 高纯度喹啉衍生物及其生产方法 |
| PL3263106T3 (pl) | 2015-02-25 | 2024-04-02 | Eisai R&D Management Co., Ltd. | Sposób tłumienia goryczy pochodnej chinoliny |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| US10654808B2 (en) * | 2015-04-07 | 2020-05-19 | Guangdong Raynovent Biotech Co., Ltd. | Tyrosine kinase inhibitor and pharmaceutical composition comprising same |
| ES2886107T3 (es) | 2015-06-16 | 2021-12-16 | Prism Biolab Co Ltd | Antineoplásico |
| AU2016309356B2 (en) | 2015-08-20 | 2021-06-24 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| KR20180086187A (ko) | 2015-10-05 | 2018-07-30 | 더 트러스티이스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | 자가포식 유동의 활성체 및 포스포리파제 d 및 타우를 포함하는 단백질 응집물의 클리어런스 및 단백질질환의 치료 |
| CA3012718A1 (en) | 2016-02-08 | 2017-08-17 | Vitrisa Therapeutics, Inc. | Compositions with improved intravitreal half-life and uses thereof |
| RU2743424C2 (ru) | 2016-02-12 | 2021-02-18 | Астеллас Фарма Инк. | Производные тетрагидроизохинолина |
| WO2017168448A1 (en) | 2016-03-30 | 2017-10-05 | Council Of Scientific & Industrial Research | Silicon incorporated quinolines with anti-malarial and anti-toxoplasmosis activity |
| CN106749231B (zh) * | 2016-10-09 | 2019-03-01 | 南京纳丁菲医药科技有限公司 | 萘啶化合物和药物组合物及它们的应用 |
| CN106831711B (zh) * | 2016-12-30 | 2021-08-24 | 苏州大学 | 苯并[e][1,2,4]三嗪-1-氧衍生物及其组合物和应用 |
| MX380144B (es) | 2017-02-08 | 2025-03-12 | Eisai R&D Man Co Ltd | Composicion farmaceutica de tratamiento de tumores. |
| CN107115344B (zh) * | 2017-03-23 | 2019-06-14 | 广东众生睿创生物科技有限公司 | 酪氨酸激酶抑制剂在制备用于预防和/或治疗纤维化疾病的药物中的用途 |
| CA3061888A1 (en) | 2017-05-16 | 2018-11-22 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| CN107903210B (zh) * | 2017-12-25 | 2021-01-26 | 三峡大学 | 一种小分子抑制剂sld4650及其在制药中的应用 |
| JP7268053B2 (ja) * | 2018-01-05 | 2023-05-02 | アンスティトゥート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシャルシュ・メディカル・（インセルム） | 置換ハロキノリン誘導体、その調製方法及び適用 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3075981A (en) * | 1958-04-03 | 1963-01-29 | Sterling Drug Inc | 1-[aromatic-(lower-alkyl)]-4-(aromaticimino)-1, 4-dihydroquinolines and their preparation |
| SE317376B (no) | 1961-07-10 | 1969-11-17 | Roussel Uclaf | |
| US3272824A (en) * | 1962-12-06 | 1966-09-13 | Norwich Pharma Co | 4-amino-6, 7-di(lower) alkoxyquinolines |
| JPS4320294Y1 (no) * | 1964-10-31 | 1968-08-26 | ||
| FR2077455A1 (en) * | 1969-09-03 | 1971-10-29 | Aries Robert | 5-haloveratryl-4-aminoquinoles - antimalarials amoebicides anthelmintics anticoccidials |
| US3755332A (en) * | 1971-07-01 | 1973-08-28 | Ciba Geigy Corp | Substituted 4 indazolaminoquinolines |
| US3936461A (en) * | 1973-09-24 | 1976-02-03 | Warner-Lambert Company | Substituted 4-benzylquinolines |
| FR2498187A1 (fr) * | 1981-01-16 | 1982-07-23 | Rhone Poulenc Sante | Procede de preparation d'amino-4 chloro-7 quinoleines |
| EP0222839A4 (en) * | 1985-05-17 | 1988-11-09 | Univ Australian | ANTI-MALARIA COMPOUNDS. |
| IL81307A0 (en) | 1986-01-23 | 1987-08-31 | Union Carbide Agricult | Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives |
| IL89029A (en) * | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
| ES2108120T3 (es) | 1991-05-10 | 1997-12-16 | Rhone Poulenc Rorer Int | Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf. |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| EP0586608A1 (en) * | 1991-05-29 | 1994-03-16 | Pfizer Inc. | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
| JPH06504294A (ja) * | 1991-08-02 | 1994-05-19 | ファイザー・インコーポレーテッド | 免疫刺激剤としてのキノリン誘導体 |
| GB9127252D0 (en) | 1991-12-23 | 1992-02-19 | Boots Co Plc | Therapeutic agents |
| US5712395A (en) | 1992-11-13 | 1998-01-27 | Yissum Research Development Corp. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
| US5792771A (en) | 1992-11-13 | 1998-08-11 | Sugen, Inc. | Quinazoline compounds and compositions thereof for the treatment of disease |
| US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
| US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| IL117620A0 (en) | 1995-03-27 | 1996-07-23 | Fujisawa Pharmaceutical Co | Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same |
| WO1996040648A1 (en) | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Quinazolines and pharmaceutical compositions |
| US5650415A (en) | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
| US5773459A (en) | 1995-06-07 | 1998-06-30 | Sugen, Inc. | Urea- and thiourea-type compounds |
| JP4146514B2 (ja) | 1995-07-06 | 2008-09-10 | ノバルティス アクチエンゲゼルシャフト | ピロロピリミジン類およびその製造方法 |
| GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| US6143764A (en) * | 1995-11-07 | 2000-11-07 | Kirin Beer Kabushiki Kaisha | Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab, Soedertaelje | 4-anilinochinazolin derivate |
| EP0888310B1 (en) | 1996-03-15 | 2005-09-07 | AstraZeneca AB | Cinnoline derivatives and use as medicine |
| AU5533996A (en) | 1996-04-04 | 1997-10-29 | University Of Nebraska Board Of Regents | Synthetic triple helix-forming compounds |
| GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
| EP0912559B1 (en) | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| DK0882717T3 (da) | 1996-10-01 | 2010-12-13 | Kyowa Hakko Kirin Co Ltd | Nitrogenholdige heterocykliske forbindelser |
| KR20000057228A (ko) | 1996-11-27 | 2000-09-15 | 디. 제이. 우드, 스피겔 알렌 제이 | 축합된 비사이클릭 피리미딘 유도체 |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| AR016817A1 (es) | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento |
| WO1999010349A1 (en) | 1997-08-22 | 1999-03-04 | Zeneca Limited | Oxindolylquinazoline derivatives as angiogenesis inhibitors |
-
1997
- 1997-09-23 AT AT97941115T patent/ATE300521T1/de not_active IP Right Cessation
- 1997-09-23 NZ NZ334125A patent/NZ334125A/xx unknown
- 1997-09-23 CA CA002263479A patent/CA2263479A1/en not_active Abandoned
- 1997-09-23 US US09/254,440 patent/US6809097B1/en not_active Expired - Fee Related
- 1997-09-23 EP EP97941115A patent/EP0929526B1/en not_active Expired - Lifetime
- 1997-09-23 AU AU43137/97A patent/AU733551B2/en not_active Ceased
- 1997-09-23 WO PCT/GB1997/002587 patent/WO1998013350A1/en not_active Ceased
- 1997-09-23 DE DE69733825T patent/DE69733825T2/de not_active Expired - Fee Related
- 1997-09-23 CN CNB971999295A patent/CN1252054C/zh not_active Expired - Fee Related
- 1997-09-23 JP JP10515386A patent/JP2001500890A/ja active Pending
- 1997-09-23 KR KR1019997002502A patent/KR100567649B1/ko not_active Expired - Fee Related
- 1997-09-23 IL IL12899497A patent/IL128994A/en not_active IP Right Cessation
-
1999
- 1999-03-24 NO NO19991423A patent/NO321003B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20000048575A (ko) | 2000-07-25 |
| NZ334125A (en) | 2000-10-27 |
| US6809097B1 (en) | 2004-10-26 |
| DE69733825D1 (de) | 2005-09-01 |
| EP0929526A1 (en) | 1999-07-21 |
| CN1252054C (zh) | 2006-04-19 |
| DE69733825T2 (de) | 2006-06-08 |
| IL128994A0 (en) | 2000-02-17 |
| WO1998013350A1 (en) | 1998-04-02 |
| JP2001500890A (ja) | 2001-01-23 |
| AU4313797A (en) | 1998-04-17 |
| IL128994A (en) | 2004-12-15 |
| EP0929526B1 (en) | 2005-07-27 |
| ATE300521T1 (de) | 2005-08-15 |
| CN1237963A (zh) | 1999-12-08 |
| NO991423L (no) | 1999-05-11 |
| NO321003B1 (no) | 2006-02-27 |
| CA2263479A1 (en) | 1998-04-02 |
| KR100567649B1 (ko) | 2006-04-05 |
| AU733551B2 (en) | 2001-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO991423D0 (no) | Qinolinderivater som inhiberer effekten av vekstfaktorer som VEGF | |
| CA2344290A1 (en) | Quinazoline derivatives | |
| DK0873319T3 (da) | Quinazolinderivater | |
| PL328310A1 (en) | Derivatives of quinazoline | |
| CA2263319A1 (en) | Quinazoline derivatives and pharmaceutical compositions containing them | |
| EP1259487B8 (en) | 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors | |
| MXPA03000252A (es) | Derivados de quinolina que tienen actividad de inhibicion de fcev. | |
| MXPA01004256A (es) | N-arilamidas del acido antranilico y del acido tioantranilico. | |
| NO20030624L (no) | Cinnolinforbindelser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |